Skip to main content

Table 1 Demographic and Clincial Data

From: Hypophosphatasia and the risk of atypical femur fractures: a case–control study

  Atypical femur fracture Control P value
Number of patients 10 13  
Mean age in years (range) 71 (68–79) 68 (62–84) 0.27
Female (%) 9/10 (90 %) 10/13 (77 %) 0.45
Bisphosphonate used
 Alendronate 7 (70 %) 10 (77 %) 0.68
 Ibandronate 2 (20 %) 3 (23 %)  
 Risendronate 1 (10 %) 0  
Proportion of patients with Vitamin D supplementation (%) 6/10 (60 %) 6/13 (46 %) 0.68
Mean years of bisphosphonate use (range) 9.2 (5–13) 8.8 (5–20) 0.79
Mean years since bisphosphonates stopped 3.6 (1–5) 2.0 (1–4)a 0.65
Mean alkaline phosphatase in U/L (range)c 58 (37–73) 56 (38–74) 0.81
Proportion of patients with abnormal alkaline phosphatase (below 50 U/L) 5/10 (40 %) 5/13 (38 %)  
Mean pyridoxal 5’ phosphate (PLP) in mcg/Ld 29.8 (5–44) 20.6 (5–118) 0.37
Mean neck-shaft angle degrees (S.D.) 132 (3.1) 136 (5.2) 0.048
Mechanical axis angle degreesb (S.D.) −0.71 (5.0) −0.15 (2.7) 0.76
Lateral distal femoral angle degrees (S.D.) 90.7 (5.0) 90.2 (2.7) 0.76
  1. a10 of the thirteen patients had discontinued bisphosphonates. Three were continuing
  2. bA positive number represents valgus alignment
  3. cNormal range 55 to 105 U/L
  4. dNormal range 5 to 50 mcg/L